Molecular Monitoring Improves Survival in Some Patients With Newly Diagnosed Leukemia
By Elana Gotkine HealthDay Reporter
WEDNESDAY, May 14, 2025 -- Molecular monitoring of measurable residual disease (MRD), coupled with guided treatment, contributes to improved survival for patients with newly diagnosed acute myeloid leukemia (AML) with NPM1 and FLT3 mutations, but it does not improve overall survival in the entire patient population, according to a study published online in the May issue of The Lancet Haematology.
Nicola Potter, Ph.D., from King's College London, and colleagues examined whether altering treatment based on MRD results can improve survival in patients aged 16 to 60 years with newly diagnosed AML enrolled in two trials. Patients were screened for molecular markers suitable for disease monitoring, including NPM1 mutations and fusion genes. Those with a marker were randomly assigned to receive sequential molecular MRD monitoring during treatment and for three years after or to standard clinical care with no molecular monitoring (289 to MRD monitoring and 144 to no monitoring in the AML17 trial and 136 to MRD monitoring and 68 to no monitoring in the AML19 trial).
The researchers found that overall survival at three years was 70 and 73 percent in patients in the monitoring and no-monitoring groups, respectively, with a median follow-up time of 4.9 years. No difference was seen in overall survival in a meta-analysis of the two studies. In patients with both NPM1 and FLT3 internal tandem duplication (ITD) mutations, overall survival at three years was 69 and 58 percent in the monitoring and no-monitoring groups, respectively (hazard ratio, 0.53). In patients with NPM1 mutations without FLT3-ITD or those with fusion gene transcripts, no difference in survival was seen by random assignment.
"There is still so much to learn about how best to treat this fast-moving form of cancer," study coauthor Nigel Russell, M.D., from Guy’s and St. Thomas’ NHS Foundation Trust in London, said in a press release. "We hope our research offers a new approach to detecting if a patient is at risk of relapse and offers hope to patients suffering from this disease.”
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Socioeconomic Status Tied to New Diagnosis of Hidradenitis Suppurativa
WEDNESDAY, May 14, 2025 -- For dermatology patients, neighborhood-level socioeconomic status (nSES) is associated with a new diagnosis of hidradenitis suppurativa (HS), according...
AI Tools Can Predict Left Ventricular Dysfunction in Women of Reproductive Age
WEDNESDAY, May 14, 2025 -- Artificial intelligence (AI) tools are effective for detecting left ventricular systolic dysfunction (LVSD) among women of reproductive age seen in...
Aqueous Humor Liquid Biopsy Safe in Pediatric Retinoblastoma
WEDNESDAY, May 14, 2025 -- For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.